In a previous report in Clinical Chemistry, we described much higher international normalized ratios (INRs) 1 with recombinant Neoplastin R (Roche Diagnostics) than with tissue-extract Neoplastin Plus (Roche Diagnostics) in patients initiating oral anticoagulant therapy (1 ) . For patients on stable oral anticoagulation, we observed no significant differences in INRs between the thromboplastins. The increased INR values with Neoplastin R during unstable anticoagulation, such as in the initial phase of oral anticoagulation treatment, could be explained by fluctuations in coagulation factor VII (FVII) concentrations owing to the low half-life of FVII. Recombinant thromboplastin exhibits an increased sensitivity for FVII compared with tissue-derived thromboplastin (2, 3 ) . The difference in sensitivity between Neoplastin R and Neoplastin Plus for FVII could implicate alterations in anticoagulation dosage and time period in obtaining stable anticoagulation. We investigated whether our findings could be extrapolated to other recombinant thromboplastins.
We collected and citratetreated blood samples from 20 patients in the initial phase of oral anticoagulation treatment (between day 3 and day 7 after starting with a standard loading dosage of acenocoumarol: day 1, 6 mg; day 2, 4 mg; day 3, 2 mg), 20 patients with a highly increased INR (Ͼ5) not yet stabilized on oral anticoagulation, and 20 patients on stable oral anticoagulation (within the therapeutic INR interval of 2.0 -4.0). Prothrombin time was measured on a STA-R analyzer (Roche Diagnostics). The international sensitivity index (ISI) was calibrated for each thromboplastin against reference plasma that had been primarily calibrated against the international reference standard, in accordance with guidelines (4 We found increasing differences in the INR between recombinant thromboplastins (Innovin, RecombiPlasTin, Neoplastin R) and tissue-extract thromboplastins (Hepatoquick, Thromborel S, Neoplastin Plus) with increasing INR for all of the tested thromboplastins. In Fig. 1 
Role of Sponsor:
The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
